Mode
Text Size
Log in / Sign up
N/A N=354 Randomized Single-blind Supportive Care

Pharmacological and Non-pharmacological Interventions in Management of Venipuncture Pain.

Child, Hospitalized

Enrolled (actual)
354
Serious AEs
0.0%
Results posted
Oct 2021
Primary outcome: Primary: Child Self-reported Pain: Wong-Baker Faces Pain Rating Scale — 2; 2; 2 score on a scale — p=0.511

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
EMLA application (Drug); Distraction techniques (Behavioral); EMLA cream and distraction techniques (Other)
Age
Pediatric · 3+ yrs
Sex
All
Sponsor
Children's Hospital of Fudan University
Primary completion
Apr 2020

Outcome Measures

OutcomeResultp-value
PRIMARY
Child Self-reported Pain: Wong-Baker Faces Pain Rating Scale
2; 2; 2 0.511
PRIMARY
Parents Reported Pain (Outcomes Assessor ): Revised Faces, Legs, Activity, Cry, Consolability Behavioral Pain Rating Scale (r-FLACC)
0; 0; 0 0.072
PRIMARY
Observer Reported Pain (Parents): Revised Faces, Legs, Activity, Cry, Consolability Behavioral Pain Rating Scale (r-FLACC)
1; 1; 1 0.906
SECONDARY
Concentration of Salivary Cortisol
35.47; 32.02; 37.7 0.035 sig
SECONDARY
Heart Rate
104.02; 102.49; 103.65 0.844
SECONDARY
Pulse Oximetry Saturation
98; 98; 99 0.438
SECONDARY
Retaining Time of Intravenous Cannula
15; 15; 21 0.843
SECONDARY
Venipuncture Duration
83; 83; 85.5 0.440

Summary

To evaluate whether an integration of pharmacological and non- pharmacological interventions is more effective than either one of intervention in pain reduction during pediatric peripheral venipuncture.

Eligibility Criteria

Inclusion Criteria

Children aged 3-16 years who receive first peripheral intravenous puncture during hospitalization.

Exclusion Criteria

  • Emergency peripheral intravenous puncture.
  • Allergic history for lidocaine cream.
  • Presence of cognitive impairment, hearing impairment or visual impairment.
  • Children who were discharged from the hospital after participating in the experiment but were readmitted due to illness.
  • Refuse to participate in the study.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04275336). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search